Eli Lilly | LLY - Nettoeinkommen





Nettoeinkommen Veränderung Datum
AbbVie USD 4.22B 605M 2026-09
Abbott USD 920M 8M 2026-09
ALKERMES USD 16.29M 15.79M 2026-09
Amgen USD 3.86B 1.49B 2026-09
AstraZeneca USD 3.12B 610M 2026-09
Baxter International USD 294M 168M 2026-09
Biogen USD 97.5M 222M 2026-06
Bristol-Myers Squibb USD 2.16B 1.16B 2026-09
Coherus Biosciences USD -37.64M 2.11M 2025-12
Drreddys Laboratories INR 9.25B 7.04B 2026-09
Eli Lilly USD 7.1B 301M 2026-06
Gilead Sciences USD -10.5B 12.52B 2026-06
GlaxoSmithKline GBP 1.54B 1.11B 2026-09
Glaxosmithkline GBP 1.54B 194M 2026-09
J&J USD 210M 5.32B 2026-09
Medtronic USD 1.47B 227M 2026-06
Merck USD 5.07B 6.4B 2026-09
Neurocrine Biosciences USD 206.5M 62.1M 2026-09
Novartis USD 1.2B 2.06B 2026-09
Novartis USD 1.2B 1.95B 2026-09
Novo Nordisk DKK 20.99B 5.9B 2026-06
Perrigo USD -27.5M 102M 2026-09
Pfizer USD 3.24B 3.49B 2026-09
Phibro Animal Health USD 27.46M 932K 2025-12
Prestige Brands USD 38.54M 15.39M 2026-06
Regeneron Pharmaceuticals USD 1.3B 569.7M 2026-06
Roche Holding CHF 6.87B 1.4B 2026-06
Sanofi EUR 3.02B 2.68B 2026-09
Sanofi EUR 343M 1.27B 2026-06
United Therapeutics USD 258.6M 74.4M 2026-09
Zoetis USD 591M 100M 2026-09